Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study of patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF (trifluridine and tipiracil) or Stivarga (regorafenib)

Trial Profile

A retrospective study of patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF (trifluridine and tipiracil) or Stivarga (regorafenib)

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Regorafenib
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Oct 2018 New trial record
    • 28 Sep 2018 According to a Taiho Oncology media release, data will be presented at the 2018 ASCO Quality of Care Symposium (ASCO QCS) by Anuj Patel of Dana-Farber Cancer Institute.
    • 28 Sep 2018 Results published in the Taiho Oncology Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top